Trelstar (Triptorelin Pamoate) Patent Expiration, LOE Window & CMS Spending

Trelstar (Triptorelin Pamoate) by Verity: FDA Orange Book LOE 2029-06-30, 0 AB generics, $16.7M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVerity
FDA Application & PathwayN020715 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-06-30
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$16.7M
2024 Medicare Part D Spend$15.3M
2024 Medicaid Spend$1.4M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 18.0% 2-yr change)